General MedicationsTOPICALGeneric
AKNE-MYCIN
ERYTHROMYCIN
Standard Dose
2%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview AKNE-MYCIN is listed in Drugs@FDA under application 050584 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength OINTMENT;TOPICAL - 2% Sponsor BAUSCH Submission history Latest submission status date: 2001-02-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview AKNE-MYCIN is listed in Drugs@FDA under application 050584 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength OINTMENT;TOPICAL - 2% Sponsor BAUSCH Submission history Latest submission status date: 2001-02-28 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.